Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Dermatologic 2Thoracic 1Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 8Nivolumab 6Gemcitabine 5spartalizumab 3Magnetic Resonance Spectroscopy 3Cyclophosphamide 3Azacitidine 3toripalimab 2fludarabine 2epacadostat 2atezolizumab 2Therapeutics 2Sirolimus 2Paclitaxel 2Interleukin-2 2Epoetin Alfa 2Cisplatin 2Bevacizumab 2vocimagene amiretrorepvec 1vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1temsirolimus 1sargramostim 1sapanisertib 1ruxolitinib 1rucaparib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Proteasome Inhibitors × Thoracic × Clear all
NCT00667082 2017-11-22

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Celgene

Phase 1 Completed
22 enrolled
DermatologicGastrointestinalLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Multiple Myeloma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡